Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CSL ( (AU:CSL) ).
CSL Limited has provided an updated notification to the ASX on its ongoing on-market share buy-back program covering its ordinary fully paid shares. The latest filing, dated 27 March 2026, reports that the company had repurchased a total of 5,091,427 shares prior to the most recent trading day and bought back a further 89,271 shares on the previous day.
The continued daily execution of the buy-back suggests CSL is actively returning capital to shareholders while potentially managing its capital structure and supporting its share price. Regular updates on the program’s progress offer transparency for investors and may signal management’s confidence in the company’s long-term value and earnings outlook.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$149.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, best known for its specialty biopharmaceuticals and plasma-derived therapies. The group focuses on developing and manufacturing vaccines, blood plasma products, and innovative treatments for serious and rare diseases, serving hospitals, healthcare systems, and patients worldwide.
Average Trading Volume: 1,236,033
Technical Sentiment Signal: Sell
Current Market Cap: A$68.43B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.